Kairos Pharma (KAPA) EBIT Margin (2024 - 2025)

Kairos Pharma's (KAPA) quarterly EBIT Margin came in at 2.91% in Q2 2025, down 15.01% on a QoQ basis from 2.53% in Q1 2025.

Kairos Pharma (KAPA) EBIT Margin (2024 - 2025) Analysis & Trends

Kairos Pharma (KAPA) has 2 years of EBIT Margin data on file, last reported at 2.91% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	139.65 Bn	131.79 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	86.08 Bn	78.09 Bn	3.93 Bn	30.15%
3	Argenx Se	65.16 Bn	59.98 Bn	1.37 Bn	32.54%
4	Moderna	63.25 Bn	58.11 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	42.22 Bn	37.12 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.26 Bn	27.95 Bn	992.69 Mn	17.93%
7	BioNTech SE	28.96 Bn	10.57 Bn	668.28 Mn	-35.57%
8	Insmed	27.40 Bn	26.24 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.19 Bn	26.35 Bn	-	19.75%
10	Kairos Pharma	5.55 Mn	218,135.11	-	-

Download Data